Characteristics | Tocilizumab group (N, %) | Usual care group (N, %) | p value |
---|---|---|---|
Number of patients Age (median, %95 CI) Male sex/Female sex Current/ Ex-smokers/Never smokers Arterial hypertension Dyslipidemia Diabetes mellitus Depression Obesity Hypothyroidism Chronic heart disease Cancer WHO clinical progression scale day1(mean ± SD) PaO2/FiO2 day 1 (median, 95% CI) C-reactive protein (mg/dL, median, 95% CI) D-dimer (μg/ml, median,95% CI) Ferritin (ng/ml, median, 95% CI) White blood cells (/μL,median,95% CI) Polymorphonuclear leukocytes (/μL, median, 95% CI) Lymphocytes (/μL, median, 95% CI) RDW (%, median, 95% CI) | 56 66.0 (60.0 to 70.0) 33 (58.9%)/23 (41.1%) 5 (8.9%)/18 (32.1%)/33 (58.9%) 29 (51.8%) 17 (30.3%) 13 (23.2%) 11 (19.6%) 9 (16.1%) 8 (14.3%) 6 (10.7%) 4 (7.1%) 5.3 ± 0.5 154.5 (130.0 to 165.0) 7.5 (4.7 to 9.6) 0.82 (0.61 to 1.18) 765.0 (545.5 to 1191.9) 6190.0 (5467.9 to 6882.2) 5120.0 (4319.9 to 5688.0) 735.0 (654.0 to 818.0) 14.2 (13.5 to 14.4) | 58 66.5 (62.1 to 72.0) 36 (62.1%)/22 (37.9%) 10 (17.2%)/ 13 (22.4%)/35 (60.3%) 25 (43.1%) 7 (12.1%) 14 (24.1%) 6 (10.3%) 6 (10.3%) 6 (10.3%) 11 (18.9%) 6 (10.3%) 5.1 ± 0.5 157.0 (131.9 to 162.9) 8.5 (6.5 to 11.5) 0.84 (0.65 to 1.19) 644.5 (493.3 to 837.1) 5915.0 (5400.0 to 7657.2) 4565.0 (3936.7 to 5857.0) 815.0 (692.7 to 920.0) 14.0 (13.4 to 15.1) | NA 0.51 0.72 0.19/0.25/0.88 0.35 0.02 0.91 0.16 0.36 0.52 0.22 0.55 0.75 0.69 0.09 0.80 0.43 0.84 0.75 0.13 0.21 |